BTIG downgraded Organogenesis (ORGO) to Neutral from Buy without a price target following the Q1 report. The company’s Advanced Wound Care recovery is taking longer to play out with limited clarity as to when it may actually occur, the analyst tells investors in a research note. The firm says multiple factors have materially slowed the market, creating confusion, limiting utilization, and driving physicians to less advanced dressings to treat wounds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis completes rolling submission of ReNu BLA
- Morning News Wrap-Up 4/7/26: Tuesday’s Biggest Stock Market Stories!
- Midday Fly By: Health insurers get ‘positive surprise’ from CMS
- Video: Health insurers rise after CMS finalizes 2027 Medicare payment hike
- Morning Movers: Broadcom gains following pact to supply custom TPUs for Google